Page 4 - Ancer Prostate News Today

Perhaps one of your patients could benefit from clinical trials that have started recruiting patients with prostate cancer.

A 2023 update of the Beers Criteria was released in May 2023 after panel review of more 1500 clinical trials and research studies published since the last update.

Researchers characterized the tool as "an important first step in the development and testing of interventional strategies that may ultimately halt disease progression."

Researchers report that they have found epigenetic methylation markers on 15 genes that appear to foreshadow psoriatic arthritis.

The combination, along with prednisone, is approved for adult patients with BRCA-positive castration-resistant prostate cancer, as determined by an FDA-approved test.

Their link with metastases, and thus with aggressive tumors, gives them an advantage over other biomarkers in the early identification of invasive tumors for therapeutic intervention.

More than half of patients with advanced cancer would not want a treatment that delays time to progression without any improvement in overall survival.

MRI-guided stereotactic body radiotherapy not only provides more precise delivery of prostate radiation but also pays off in fewer genitourinary and bowel side effects, new research shows.

Using early-response biomarkers in patients treated with lutetium-177 PSMA-617 can help personalize dosing intervals and potentially improve outcomes.

The newly approved device from Urotronic relieves enlarged prostate symptoms without requiring burns or implants.